Lakefront Biotherapeutics is a biotechnology company focused on developing medicines for patients with serious diseases, primarily in immunology and inflammation. The company operates as a single segment, leveraging deal-making expertise to identify, acquire, and advance clinical-stage assets. Its current pipeline is anchored by gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases such as autoimmune hemolytic anemia and immune thrombocytopenia, which was acquired through the Ouro Medicines transaction. The company previously maintained a cell therapy portfolio including CAR-T candidates for oncology, but initiated the wind-down of these activities in early 2026 to refocus resources on strategic business development. Lakefront Biotherapeutics was formerly known as Galapagos NV, a name it used until April 2026, and was incorporated in 1999. The company collaborates with Gilead Sciences on next-generation T-cell engager therapies and has in-licensed additional preclinical autoimmune programs. Its business model prioritizes modality-agnostic asset selection and operational flexibility to build a differentiated clinical-stage portfolio.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lakefrontbio.com
Sector Healthcare IR page lakefrontbio.com/investors
Tags
immunology, inflammation, t-cell engagers, autoimmune diseases, oncology, cell therapy, car-t, business development, asset acquisition, clinical-stage pipeline, gamgertamig, OM336, GLPG3667, GLPG5101, GLPG5301, Ouro Medicines, Gilead Sciences, CellPoint, AboundBio, Alfasigma, Jyseleca
Press page —

Metrics

Valuation  
Market cap € 1.954B
Market cap (USD) $ 2.143B
P/E 5.36
PEG —
P/BV 0.53
P/S 3.55
P/OCF -3.42
P/FCF -3.08
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.5%
ROI 10.2%
ROIC 9.4%
Profit margin 28.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 68
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021
Revenue 275.649M 239.724M 241.249M 234.384M
Net profit 74.082M 211.697M -217.991M -103.231M
Free cash flow -402.136M -425.243M -537.491M -561.706M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Lakefront Creates New Subscription Right Plan Bull 0 Bear 1 Routine

Mechelen, Belgium; November 18, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced that its Board of Directors has created 150,000 subscription rights under a new subscription right plan on November 10, 2026.

On November 10, 2026, the Board of Directors of Lakefront approved the “Subscription Right Plan November 2026”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 150,000 subscription rights were created for compensation of current and potential future employees. Each subscription right gives the right to subscribe to one new Lakefront share. More information can be found in the Board report published on the Lakefront website at Special reports | Lakefront Biotherapeutics (https://lakefrontbio.com/investors/corporate-governance/special-reports/).

Lakefront’s total share capital currently amounts to €356,444,938.61; the total number of securities conferring voting rights is 65,897,071, which is also the total number of shares (the “denominator”).

Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026.

Under the initial program, completed on October 16, 2026, Lakefront repurchased approximately 1.99 million ordinary shares for a total consideration of €50 million. The repurchased shares are held as treasury shares.

The new program will be carried out by Morgan Stanley & Co International PLC, acting as an independent financial intermediary under a discretionary mandate and making its trading decisions independently of Lakefront. Purchases will be made in the open market on Euronext under the terms and conditions approved by the Extraordinary Shareholders’ Meeting on April 28, 2026, and executed in accordance with industry best practices.

In accordance with the limits of the repurchase authorization granted, under the program, the Company may repurchase up to 4,604,550 ordinary shares for an aggregate amount of up to €50 million.

Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.

A live webcast of the presentation will be accessible on the Investors page of the Company’s website at Webcasts & Events - Lakefront Biotherapeutics. A replay of the webcast will be available following the completion of the event and will be archived for up to 90 days.

About Lakefront Biotherapeutics

Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases.

Prompts

Lakefront Biotherapeutics (ticker LKFT), listed in United States.

Company History

Date Change Detail
May 8, 2026 Renamed GALAPAGOS NV → Lakefront Biotherapeutics NV
— Former tickers GLPG

ETFs Holding Lakefront Biotherapeutics

ETF Weight in ETF Shares Market value As of
ESIM 0.11% 695 $ 19.079K Jul 31, 2026
AVDS 0.07% 7,605 $ 264.578K Nov 16, 2026
APIE 0.05% 19,649 $ 559.997K Aug 31, 2026
AVDE 0.01% 39,584 $ 1.377M Nov 16, 2026
CORO 0.01% 47,246 $ 1.623M Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
GLPG delisted Common share — NL euronext — —
LKFT canonical Common share — US nasdaq 29.65 USD 2026-09-30
LKFT Common share — NL euronext — —